Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) (A DUE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03904693 |
|
Recruitment Status :
Active, not recruiting
First Posted : April 5, 2019
Results First Posted : November 13, 2023
Last Update Posted : May 10, 2024
|
Sponsor:
Actelion
Information provided by (Responsible Party):
Actelion
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of targeting different pathways known to be involved in the pathogenesis of the disease. Adherence to prescribed therapy has an impact on clinical outcomes. Reducing the pill/tablet count and frequency has a major impact on patients' adherence to therapies and therefore the observed clinical outcomes. One way to simplify treatment is to use fixed-dose combination (FDC) products that combine multiple treatments targeting different pathways into a single tablet.
This study aims to demonstrate that the FDC of macitentan and tadalafil is more effective than therapy with 10 mg of macitentan alone or 40 mg of tadalafil alone. This phase 3 study will evaluate the efficacy and safety at 16 weeks of an FDC (macitentan 10 mg and tadalafil 40 mg) against these two PAH-approved therapies given as monotherapy to further confirm the added value of the FDC.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Drug: FDC macitentan/tadalafil Drug: Macitentan 10 mg Drug: Tadalafil 40 mg Drug: Placebo FDC Drug: Placebo macitentan Drug: Placebo tadalafil | Phase 3 |
PAH is characterized by a progressive increase in pulmonary arterial pressure (PAP) and in pulmonary vascular resistance (PVR) potentially leading to right heart failure and death. Current PAH-specific therapeutic options include treatments that target the three pathways (endothelin, nitric oxide, and prostacyclin pathways). While combination treatment is common, FDC pills or tablets that combine two or more PAH-specific therapies are not available, thereby requiring participants to take multiple pills/tablets daily. An FDC is an attractive option for PAH participants because it simplifies the treatment regimen by combining two therapies (which would otherwise involve a total of three tablets: one macitentan 10 mg tablet and two tadalafil 20 mg tablets) into a single tablet. Macitentan is an orally active, non-peptide, potent dual endothelin receptor A and B antagonist. Tadalafil is a selective inhibitor of phosphodiesterase type-5 (PDE-5), the enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP). This study comprises the following consecutive periods: Screening period (lasts up to 30 days), Double-blind treatment period (consists of the titration phase [the first 2 weeks] and the maintenance phase [Week 3 through Week 16]), Open-label treatment period, End-of-Treatment (EOT), Safety follow-up (S-FU) period, and End of Study (EOS). The total study duration for a participant will be up to 30 months. Study assessments like physical examinations, vital signs, right heart catheterization, 6-minute walk test will be performed. Safety will be assessed throughout the study.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 187 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | In total, approximately 170 subjects are planned to be randomized into study to receive either FDC macitentan/tadalafil or macitentan 10 mg or tadalafil 40 mg given once daily and will also receive matching placebos for two other study treatments. Treatment allocation will be stratified based on prior PAH therapy (i.e., treatment-naïve or treated by an Endothelin receptor antagonist or a Phosphodiesterase type-5 inhibitor as a monotherapy) at baseline. Sample size will be re-estimated at interim analysis if study is not terminated early for efficacy/futility up to sample size of 150-250. After completion of double-blind treatment period, subjects will continue study in an open-label treatment (OLT) period for 24 months, which may be prolonged beyond 24 months until macitentan and tadalafil are accessible at required doses, through other options according to local regulations. All assessments at end of double-blind treatment must be completed before subject enters OLT period. |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Prospective, Multi-center, Double-blind, Randomized, Active-controlled, Triple-dummy, Parallel-group, Group-sequential, Adaptive Phase 3 Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed Dose Combination in Subjects With Pulmonary Arterial Hypertension (PAH), Followed by an Open-label Treatment Period With Macitentan and Tadalafil Fixed Dose Combination Therapy |
| Actual Study Start Date : | July 29, 2019 |
| Actual Primary Completion Date : | August 23, 2022 |
| Estimated Study Completion Date : | September 24, 2024 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
High Blood Pressure
| Arm | Intervention/treatment |
|---|---|
|
Experimental: FDC therapy + Placebo macitentan + Placebo tadalafil
Subjects to receive FDC macitentan/tadalafil (macitentan 10 mg and tadalafil 40 mg) plus matching placebos for the two other study treatments.
|
Drug: FDC macitentan/tadalafil
Film-coated tablet with 10 mg macitentan and 40 mg tadalafil, to be administered orally once daily.
Other Name: ACT-064992D Drug: Placebo macitentan Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily. Drug: Placebo tadalafil Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily. |
|
Active Comparator: Macitentan mono-therapy + Placebo tadalafil + Placebo FDC
Subjects to receive macitentan 10 mg plus matching placebos for the two other study treatments.
|
Drug: Macitentan 10 mg
Film-coated tablet with 10 mg macitentan, to be administered orally once daily.
Other Name: ACT-064992 Drug: Placebo FDC Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily. Drug: Placebo tadalafil Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily. |
|
Active Comparator: Tadalafil mono-therapy + Placebo macitentan + Placebo FDC
Subjects to receive tadalafil 40 mg (2 x 20 mg) plus matching placebos for the two other study treatments.
|
Drug: Tadalafil 40 mg
Film-coated tablet with 40 mg tadalafil (2 x 20 mg tablets), to be administered orally once daily. Drug: Placebo FDC Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily. Drug: Placebo macitentan Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily. |
Primary Outcome Measures :
- Change in Pulmonary Vascular Resistance (PVR) Expressed as the Ratio of Geometric Means of End of Double-blind Treatment (EDBT) to Baseline [ Time Frame: Baseline, EDBT (up to 16 weeks) ]Change in PVR expressed as the ratio of geometric means of EDBT to baseline were reported.
Secondary Outcome Measures :
- Change From Baseline in 6-minutes Walking Distance (6MWD) to EDBT [ Time Frame: Baseline, EDBT (up to 16 weeks) ]
- Change From Baseline in Pulmonary Arterial Hypertension Symptoms and Impact (PAH-SYMPACT) in Cardiopulmonary Symptom Domain Scores to EDBT [ Time Frame: Baseline, EDBT (up to 16 weeks) ]
- Change From Baseline in Pulmonary Arterial Hypertension Symptoms and Impact (PAH-SYMPACT) in Cardiovascular Symptom Domain Scores to EDBT [ Time Frame: Baseline, EDBT (up to 16 weeks) ]
- Percentage of Participants With Absence of Worsening in World Health Organization (WHO) Functional Class (FC) From Baseline to EDBT [ Time Frame: Baseline, EDBT (up to 16 weeks) ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Signed and dated informed consent form (ICF)
- Confirmed diagnosis of symptomatic PAH in WHO FC II or III
-
Symptomatic PAH belonging to one of the following subgroups of WHO Group 1 pulmonary hypertension:
- Idiopathic
- Heritable
- Drug- or toxin-induced
- Associated with connective tissue disease, HIV infection, portal hypertension or congenital heart disease with simple systemic-to-pulmonary shunt with persistent pulmonary hypertension documented by a right heart catheterization (RHC) ≥ 1 year after surgical repair
-
PAH diagnosis confirmed by hemodynamic evaluation at rest (through central reading), evaluated within 5 weeks prior to randomization:
- Mean pulmonary artery pressure (mPAP) ≥ 25 mmHg, AND
- Pulmonary artery wedge pressure (PAWP) or left ventricular end diastolic pressure (LVEDP) ≤ 15 mmHg, AND
- Pulmonary vascular resistance (PVR) ≥ 3 WU (i.e., ≥ 240 dyn∙sec∙cm-5)
- Negative vasoreactivity test in idiopathic, heritable, and drug/toxin-induced PAH. (Participants for whom no vasoreactivity test was performed at diagnosis can be eligible if currently treated with PAH therapy for more than 3 months and PAH diagnosis confirmed by hemodynamic evaluation at least 3 months after introduction of their PAH therapy).
- Currently receiving a stable dose of ERA or PDE-5i monotherapy for at least 3 months prior to baseline RHC, within the prespecified doses in the study protocol or no history of PAH-specific treatment
- Participant able to perform the 6MWT with a minimum distance of 100 m and maximum distance of 450 m at Screening
-
A woman of childbearing potential must:
- have negative serum pregnancy test at Screening and a negative urine pregnancy test at Randomization
- agree to undertake monthly urine pregnancy tests during the study and up to at least 30 days after study treatment discontinuation
- agree to follow the contraception scheme from Screening up to at least 30 days after study treatment discontinuation
Exclusion Criteria:
- Treatment with a soluble guanylate cyclase stimulator, L-arginine, any form of prostanoids or prostacyclin-receptor agonists (including oral, inhaled, or infused routes) in the 3-month period prior to start of treatment
- Treatment with combination therapy of ERA and PDE-5i in the 3-month period prior to start of treatment or history of intolerance to ERA and PDE-5i combination therapy
- Hypersensitivity to any of the study treatments or any excipient of their formulations
- Treatment with a strong cytochrome P450 3A4 (CYP3A4) inducer in the 1-month period prior to start of treatment
- Treatment with a strong CYP3A4 inhibitor or a moderate dual CYP3A4/CYP2C9 inhibitor or co-administration of a combination of moderate CYP3A4 and moderate CYP2C9 inhibitors in the 1-month period prior to start of treatment
- Treatment with doxazosin
- Treatment with any form of organic nitrate, either regularly or intermittently
- Diuretic treatment initiated or dose changed within 1 week prior to the RHC or start of treatment
- Treatment with another investigational drug in the 3-month period prior to start of treatment
- Body mass index (BMI) > 40 kg/m2 at Screening
-
Known presence of three or more of the following risk factors for heart failure with preserved ejection fraction at Screening:
- BMI > 30 kg/m2
- Diabetes mellitus of any type
- Essential hypertension (even if well controlled)
- Coronary artery disease, i.e. history of stable angina or known more than 50% stenosis in a coronary artery or history of myocardial infarction or history of or planned coronary artery bypass grafting and/or coronary artery stenting
- Known presence of moderate or severe obstructive lung disease any time prior to Screening as specified in study protocol
- Known presence of moderate or severe restrictive lung disease any time prior to Screening as specified in study protocol
- Clinically significant aortic or mitral valve disease; pericardial constriction; restrictive or congestive left-sided cardiomyopathy; life-threatening cardiac arrhythmias; significant left ventricular dysfunction; or left ventricular outflow obstruction, in the opinion of the investigator
- Known permanent atrial fibrillation, in the opinion of the investigator
- Known or suspected uncontrolled thyroid disease (hypo- or hyperthyroidism)
- Documented pulmonary veno-occlusive disease
- Hemoglobin < 100 g/L (<10 g/dL) at Screening
- Known severe hepatic impairment as specified in study protocol
- Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 1.5 × upper limit of normal (ULN) at Screening
- Severe renal impairment at Screening as specified in study protocol
- Systemic hypotension at Screening or Randomization and systemic hypertension at Screening as specified in study protocol
- Acute myocardial infarction or cerebrovascular event (e.g., stroke) within the last 26 weeks prior to Screening
- Known bleeding disorder, in the opinion of the investigator
- Loss of vision in one or both eyes because of non-arteritic anterior ischemic optic neuropathy
- Hereditary degenerative retinal disorders, including retinitis pigmentosa
- History of priapism, conditions that predispose to priapism (example, sickle cell anemia, multiple myeloma, or leukemia) or anatomical deformation of the penis (example, angulation, cavernosal fibrosis, or Peyronie's disease)
- Difficulty swallowing large pills/tablets that would interfere with the ability to comply with study treatment regimen
- Any planned surgical intervention (including organ transplant) during the double-blind treatment period, except minor interventions
- Exercise training program for cardiopulmonary rehabilitation in the 12-week period prior to start of treatment, or planned to be started during the double-blind period of the study
- Pregnant, planning to become pregnant or lactating
- Any known factor or disease that might interfere with treatment adherence, full participation in the study or interpretation of the results as judged by the investigator (e.g., drug or alcohol dependence etc.)
- Known concomitant life-threatening disease with a life expectancy less than (<) 12 months
- Calcium channel blocker treatment initiated, or dose changed within 3 months prior to right heart catheterization (RHC) at screening
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03904693
Locations
Show 148 study locations
Sponsors and Collaborators
Actelion
Investigators
| Study Director: | Hany Rofael, MD | Janssen, LP |
Study Documents (Full-Text)
Documents provided by Actelion:
Documents provided by Actelion:
Study Protocol [PDF] November 21, 2022
Statistical Analysis Plan [PDF] January 31, 2023
Additional Information:
| Responsible Party: | Actelion |
| ClinicalTrials.gov Identifier: | NCT03904693 |
| Other Study ID Numbers: |
AC-077A301 2014-004786-25 ( EudraCT Number ) AC-077A301 ( Other Identifier: Actelion Pharmaceuticals Ltd ) |
| First Posted: | April 5, 2019 Key Record Dates |
| Results First Posted: | November 13, 2023 |
| Last Update Posted: | May 10, 2024 |
| Last Verified: | May 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials\transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu. |
| URL: | https://www.janssen.com/clinical-trials/transparency |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Actelion:
|
Pulmonary Arterial Hypertension PAH macitentan tadalafil fixed dose combination therapy |
Additional relevant MeSH terms:
|
Pulmonary Arterial Hypertension Familial Primary Pulmonary Hypertension Hypertension Vascular Diseases Cardiovascular Diseases Hypertension, Pulmonary Lung Diseases Respiratory Tract Diseases Tadalafil Macitentan |
Vasodilator Agents Phosphodiesterase 5 Inhibitors Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Urological Agents Endothelin A Receptor Antagonists Endothelin Receptor Antagonists Endothelin B Receptor Antagonists |